As Viatris has outperformed the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

If you are wondering whether Viatris is quietly undervalued or just a value trap in disguise, you are in the right place and we will unpack what the current price is really telling us. The stock has ...

Viatris Inc. (VTRS) delivered second-quarter 2025 adjusted earnings of 62 cents per share, which beat the Zacks Consensus Estimate of 56 cents. The company recorded adjusted earnings of 69 cents per ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. | Returning its stake in ...

Viatris ( ($VTRS) ) has provided an announcement. On December 6, 2025, Viatris Inc. announced an agreement to sell its equity stake in Biocon ...

Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m.

This was the stock's fourth consecutive day of gains.

Viatris (NASDAQ:VTRS) shares recorded modest gains in the premarket on Thursday after the Xanax maker announced positive outcomes to several Phase 3 trials alongside better-than-expected financials ...

On this news, the price of Viatris stock declined roughly 15% during the trading day, from a closing price of $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025.

Viatris ( (VTRS)) has shared an update. On November 6, 2025, Viatris reported strong financial results for the third quarter of 2025, with total revenues aligning with expectations. The company made ...

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the ...